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Abstract 
The present study offers a literature review of the main oral complications observed in women during pregnancy 
and menopause, and describes the different dental management protocols used during these periods and during lac-
tation, according to the scientific literature. To this effect, a PubMed-Medline search was made, using the following 
key word combinations: “pregnant and dentistry”, “lactation and dentistry”, “postmenopausal and dentistry”, “me-
nopausal and dentistry” and “oral bisphosphonates and dentistry”. The search was limited to reviews, metaanalyses 
and clinical guides in dental journals published over the last 10 years in English and Spanish. A total of 38 publi-
cations were evaluated. Pregnancy can be characterized by an increased prevalence of caries and dental erosions, 
worsening of pre-existing gingivitis, or the appearance of pyogenic granulomas, among other problems. Although 
routine dental treatment is generally safe in pregnant patients and posteriorly during the lactation period, certain 
dental procedures can have potentially damaging effects, such as the use of ionizing radiations, the administration 
of drugs, or the generation of pain and stress. In postmenopausal women, alterations of the oral cavity are related 
to the hormone alterations that characterize these patients and to physiological aging of the oral tissues, potentially 
giving rise to periodontitis, burning mouth syndrome and xerostomia. As a result of the development of osteoporo-
sis, these patients may be receiving treatment with oral bisphosphonates, which in turn may require changes in the 
dental management plan. 
Key words: Pregnancy, lactation, menopause, postmenopause, dental management, oral bisphosphonates.
Chaveli López B, Sarrión Pérez MG, Jiménez Soriano Y. Dental conside-
rations in pregnancy and menopause. J Clin Exp Dent. 2011;3(2):e135-44.
http://www.medicinaoral.com/odo/volumenes/v3i2/jcedv3i2p135.pdf
Article Number: 50348              http://www.medicinaoral.com/odo/indice.htm
© Medicina Oral S. L. C.I.F. B 96689336 - eISSN: 1989-5488
eMail:  jced@jced.es
e136
J Clin Exp Dent. 2011;3(2):e135-44.                                                              Pregnancy and menopause in dentistry.
Introduction
Pregnancy and the menopause are physiological chan-
ges in women that give rise to adaptive changes at both 
systemic and oral level. 
During pregnancy, women may experience systemic 
disorders such as respiratory alterations: dyspnea (60-
70% of all pregnant women), hyperventilation, snoring, 
an upper ribcage breathing pattern, chest widening and 
rhinitis (1-3); hemodynamic alterations: elevation of 
coagulation factors V, VII, VIII, X and XII, and reduc-
tion of factors XI and XIII, with increased fibrinolytic 
activity to compensate for the increased clotting tenden-
cy; gastrointestinal alterations: increased intragastric 
pressure and a reduction in lower esophageal sphincter 
tone secondary to inhibition of the production of mo-
tilin peptide hormone due to the rise in progesterone 
concentrations observed in this period – giving rise to 
heartburn (acidity) in 30-70% of all pregnant women – 
and an almost two-fold prolongation of gastric emptying 
time compared with non-pregnant women (2,3). Nausea 
and vomiting are experienced by 66% of all pregnant 
women, starting approximately 5 weeks after the last 
menstrual period, and reaching a maximum prevalence 
after 8-12 weeks. In this context, dental appointments in 
the morning are to be avoided in pregnant women with 
increased vomiting tendency due to pregnancy; renal al-
terations: increased renal perfusion particularly during 
the second half of pregnancy, giving rise to increased 
drug excretion in urine. Drug dosing adjustments are 
thus commonly required in such patients; and endocrine 
alterations: gestational diabetes is observed in 45% of 
all pregnant women. On the other hand, decubitus hypo-
tension syndrome or vena cava syndrome is observed 
in the final stage of pregnancy in approximately 8% of 
all cases, as a result of difficulty in venous return to the 
heart caused by compression of the inferior vena cava by 
the gravid uterus. This condition manifests as a sudden 
drop in blood pressure with nausea, dizziness and fain-
ting when the patient is in the horizontal position (1). In 
order to prevent this problem, pregnant women should 
keep the right hip slightly raised (10-12 cm) or inclined 
to the left while seated in the dental chair. At oral level 
there may be an increased risk of caries, periodontal di-
sease and pyogenic granulomas. 
During menopause it is possible to observe metabolic al-
terations: climacteric hyperthyroidism and parathyroid 
gland hyperactivity (due to the lack of estradiol) leading 
to calcium and phosphorus mobilization in the context 
of osteoporosis (4); cardiovascular alterations: hyper-
tensive crises (often associated to headache), tachycar-
dia and arrhythmia due to the lack of estrogens; renal 
disorders associated to estrogen dependency (interstitial 
cystitis) and diminished bladder capacity; bone altera-
tions: loss of bone mass with osteoporosis, secondary 
to the reduction in estrogen levels (observed in 25% 
of all menopausal women, and reaching 52% after 65 
years of age) – with an increased risk of hip and forearm 
fractures in the late climacteric period (5-7); psycholo-
gical and neurological disorders: irritability, insomnia, 
anxiety, depression, neuralgias, paresthesias, headache 
and restless legs syndrome due to the effect of estrogen 
depletion upon mental function. Hot flashes are the most 
common manifestation, with a frequency of 50-80% 
during climacterium, and are produced by the dilata-
tion of small blood vessels (a vascular phenomenon, but 
characterized by a strong neurovegetative component)
(4); and skin alterations in the form of epidermal atro-
phy, diminished thickness of the dermis and decreased 
elasticity, perspiration and nail growth. At oral level, a 
worsening of periodontal conditions can be seen, with 
the appearance of burning mouth syndrome, xerostomia 
(dry mouth) or maxillary osteonecrosis among women 
receiving treatment with bisphosphonates.
Material and methods
The present study offers a literature review of the main 
oral complications observed in women during pregnan-
cy and menopause, and describes the different dental 
management protocols used during these periods and 
during lactation, according to the scientific literature. To 
this effect, a PubMed-Medline search was made, using 
the following key word combinations: “pregnant and 
dentistry”, “lactation and dentistry”, “postmenopausal 
and dentistry”, “menopausal and dentistry” and “oral 
bisphosphonates and dentistry”. The search was limited 
to reviews, metaanalyses and clinical guides in dental 
journals published over the last 10 years in English and 
Spanish. A total of 108 articles were identified. After 
examining the titles and abstracts, this number was fina-
lly reduced to 35 articles, and after compiling informa-
tion from each of them we added three further articles 
(two clinical trials and a case-control study), due to their 
relevance. Thus, a total of 38 publications were finally 
considered.
Results
DENTAL CONSIDERATIONS IN PREGNANCY
1) Oral alterations during pregnancy 
At oral cavity level, pregnant women may suffer a series 
of alterations such as caries, gingivitis, periodontal di-
sease, or pyogenic granuloma. 
Caries
Pregnancy is characterized by an increased prevalence 
of dental alterations, including caries (99.38%) and ero-
sions (8). This increased risk is mainly due to the in-
crease in caryogenic microorganisms produced by the 
nutritional changes and to lesser attention to oral health, 
coinciding with a drop in salivary pH and buffer effect. 
These changes in salivary composition are observed 
in advanced-stage pregnancy and during lactation, and 
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inflammation retards the metabolism of progesterone, 
increasing the presence of the hormone in its active 
form in these tissues. As a result, in the presence of local 
irritative factors such as trauma or bacterial plaque, the 
development of pyogenic granuloma is facilitated (8). 
Clinically, the latter manifests as an asymptomatic, red, 
smooth or lobulated, sessile or pediculate mass located 
on the papillary gingival tissue and, less frequently, on 
the lip or cheek mucosa or tongue. The lesion bleeds 
easily and shows rapid growth. After delivery it decrea-
ses in size and in some cases disappears entirely.
Other alterations associated to pregnancy
Other alterations that can appear during this period are: 
aphthae, which should be monitored, though no type of 
treatment is required; salivary changes, including varia-
tions in pH and composition; an increased frequency of 
temporomandibular joint disorders, though these seem 
to be more related to dental losses, malocclusions or po-
orly executed fillings during this period (16); melasma 
(in 75% of all pregnant women), a skin alteration that 
usually improves after delivery, though it may reappear 
during successive pregnancies; and hirsutism, among 
other disorders.
2) Dental management during pregnancy 
The treatment recommendations during pregnancy 
should be viewed as general orientations, not as strict ru-
les. Interconsultation with the obstetrician or physician 
is very useful for knowing the medical condition of the 
patient, her dental needs and treatment options (17-19).
Modifications in the dental treatment plan
Phase 1: Prevention program
The most important consideration in the planning of den-
tal treatment in pregnant women is to ensure the learning 
of adequate oral hygiene (use of interproximal brushes, 
dental floss, brushing frequency and technique), with a 
view to reducing gingival inflammatory response to the 
local irritants usually associated to the hormonal chan-
ges observed during pregnancy. In addition, emphasis 
should be placed on the advisability of reducing the con-
sumption of refined carbohydrates (15).
The use and benefits of fluoride administered during the 
prenatal period for the subsequent prevention of caries 
in deciduous teeth is the subject of intense debate. Fluor 
is clearly able to cross the placental barrier and is absor-
bed by the fetus, though its true efficacy is not clear. In 
this context, Leverett et al. (20) analyzed the effect of 
prenatal fluor upon the incidence of caries in deciduous 
teeth and on the appearance of fluorosis. They adminis-
tered 1 mg of fluor daily in the form of tablets to a group 
of pregnant women during the last 6 months of preg-
nancy, while the control group received placebo. The 
subsequent incidence of childhood caries was analyzed 
after three and 5 years, together with the presence or ab-
sence of fluorosis after 5 years. The caries levels were 
very low in both groups (91% and 92% of the children 
may temporarily increase vulnerability to both caries 
and enamel erosion (9). 
Gingivitis / periodontitis
Gingivitis is the most common oral disorder during 
pregnancy, with a prevalence of 60-75% (9). Approxi-
mately 50% of all women with pre-existing gingivitis 
suffer worsening of the condition during pregnancy, as 
a result of the fluctuations in estrogen and progesterone 
levels, in combination with changes in the oral flora and 
a diminished immune response (9,10). Gingivitis tends 
to appear in the second month of pregnancy, coinciding 
with an increase in estrogen and progesterone concen-
tration. The maximum intensity is observed in the eight 
month, after which gingivitis decreases. Other factors 
such as the accumulation of dental plaque and deficient 
oral hygiene may be regarded as causal or aggravating 
factors.
Periodontitis affects approximately 30% of all pregnant 
women (9). In a study carried out by Diaz-Guzman et al. 
(8) in 7952 women (93 pregnant and 5537 non-pregnant 
subjects), no significant differences were observed in the 
prevalence of gingivitis (54.54% and 50.50%) and pe-
riodontitis (31.82% and 31.75%) between the study and 
control groups, respectively. However, the severity of 
periodontitis was significantly greater among the preg-
nant women (18.18% versus 9.88%). On the other hand, 
periodontal disease during pregnancy has been identi-
fied as a risk factor for premature delivery or low infant 
weight at birth (8,11-14). During the second trimester 
of pregnancy, the proportion of anaerobic gramnegative 
bacteria increases with respect to the aerobic bacteria in 
dental plaque. Lipopolysaccharides (bacterial compo-
nents) can activate macrophages and other cells, causing 
them to produce and secrete a broad range of molecules, 
including cytokines IL-1β, TNF-α, IL-6 and PGE2, and 
matrix metalloproteinases. If these compounds reach the 
general circulation and cross the placental barrier, the le-
vels of PGE2 and TNF-α in amniotic fluid may increase 
and premature delivery may result. The studies publis-
hed to date only report an association between these two 
conditions, but do not indicate a causal relationship. In 
any case, the inflammatory mediators produced in perio-
dontal disease have been found to also play an important 
role in the onset of labor – thus suggesting that such bio-
logical mechanisms may serve to link the two conditions 
(12-15).
Pyogenic granuloma
Pyogenic granuloma of pregnancy, also known as epulis, 
or pregnancy tumor or granuloma, is a benign, reactive 
inflammatory lesion composed of proliferating capilla-
ries, observed in 5% of all gestating women during the 
second trimester of pregnancy (9,10,14). Estrogens and 
progesterone do not intrinsically induce these lesions; 
rather, they increase the vascularity of gums which are 
already affected by gingivitis and periodontitis (8). The 
e138
J Clin Exp Dent. 2011;3(2):e135-44.                                                              Pregnancy and menopause in dentistry.
in the treatment group and control group without ca-
ries, respectively), and mild fluorosis was recorded in 
only a small proportion of children. These results do not 
confirm the hypothesis that prenatal fluor is closely re-
lated to the appearance of fluorosis or that it has a strong 
caries-preventing effect. In addition, it should be noted 
that for ethical reasons both groups were encouraged to 
use postnatal fluor, and this could have contributed to 
the diminished presence of caries in both patient popu-
lations (20). 
Phase 2: Programming of treatment during pregnancy
Fetal organogenesis takes place in the first three months 
of pregnancy, and is very sensitive to external factors 
(drugs, maternal stress, irradiation). Over the next tri-
mesters the fetus grows and becomes less sensitive – 
though a number of factors can still exert an influence, 
such as infections or certain drugs such as the tetracycli-
nes (Fig. 1)(21). 
- During the first trimester (from conception to week 
14) only emergency dental treatment is indicated, 
avoiding elective dental procedures because of the 
vulnerability of the fetus. Oral hygiene should be re-
inforced, with plaque control and tartrectomy where 
required.
- The second trimester (from week 14 to week 28) is 
the safest period for elective dental treatment. It is 
advisable to avoid X-rays during this period, though 
if they prove necessary, they should be obtained un-
der specific protective measures. It is preferable to 
postpone extensive reconstructions or major surgical 
procedures until after delivery.
- The first part of the third trimester (from week 29 
to delivery) is still a good period for elective dental 
treatment. Keeping the patient sitting for long periods 
of time is not advisable, since supine hypotension 
syndrome might develop. However, in the second half 
of the third trimester, all elective dental treatments 
should be postponed, due to the risk of premature de-
livery.
Another subject of controversy is the use of dental X-
rays. Irradiation is to be avoided during pregnancy, par-
ticularly in the first trimester (2,9). However, if X-rays 
prove necessary, they should be obtained under adequa-
te safety conditions (beam collimation, high-speed film, 
filter, lead protection, high kV setting or constant beams, 
in-use quality program), and only selected periapical or 
bitewing images should be contemplated in most cases.
Regarding drug use during pregnancy, the main concern 
is the possibility that fetal toxicity or teratogenicity may 
result if the drug is able to cross the placental barrier. Po-
lytherapy is to be avoided, and any necessary prescrip-
tion should be decided administering the least effective 
dose for the shortest period of time possible. In any case, 
medication should be avoided in the first three months of 
pregnancy. Before prescribing or administering a drug to 
a pregnant patient, the dental professional should know 
the classification of the United States Food and Drug 
Administration (FDA) for the prescription of drugs to 
pregnant women according to the risk of fetal damage. 
This classification contemplates 5 categories (A, B, C, D 
Fig. 1. Algorithm for dental management in pregnant women.
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and X)(1,2,9). In this context it is advisable to prescri-
be drugs belonging to groups A and B. However, many 
group C drugs are also administered during pregnancy 
(Table 1).
Phase 3: Lactation period
During the lactation period it is necessary to assess the 
possible risk of maternal drug use for the breastfeeding 
infant, and to evaluate the possible safer alternatives. If 
medication proves necessary, however, it should be ad-
ministered after breastfeeding, in order to facilitate eli-
mination of the drug before the next feeding time and 
thus minimize exposure of the nursing infant. It is ad-
visable to administer the medication immediately after 
breastfeeding, and to avoid further medication for four 
hours or more in order to lessen the drug concentration 
in breast milk. Oral rinses containing ethanol are not 
recommended, since the latter can be excreted in milk. 
The existing information in the case of chlorhexidine 
rinses is limited, though the scant absorption of this drug 
makes problems for the nursing infant unlikely. Table 2 
shows the drugs most commonly used in dental practice 
during lactation (21,22).
DENTAL CONSIDERATIONS IN MENOPAUSE
Menopause is a physiological process characterized by 
DRUG FDA CATEGORY USE DURING PREGNANCY
Local anesthetics:
Lidocaine• 
Mepivacaine• 
Prilocaine• 
Bupivacaine• 
Ethidocaine• 
B
C
B
C
B
YES
YES (with caution)
YES
YES (with caution)
YES
Analgesics:
Acetylsalicylic acid• 
Acetaminophen• 
Ibuprofen• 
COX-2 inhibitors• 
Codeine• 
Oxycodone• 
Morphine• 
Fentanyl• 
Naproxen• 
C/D
B
B/C
C
C
B/C
B
B
B/D
NO
YES
Avoid in third trimester
Avoid in third trimester
Can be used in second and third trimester
YES
YES
YES
NOT in second half of pregnancy
Antibiotics:
Amoxicillin• 
Metronidazole• 
Erythromycin• 
Penicillin V• 
Cephalosporins• 
Gentamycin• 
Clindamycin• 
Cephalosporins• 
Tetracyclines• 
Chlorhexidine• 
B
B
B
B
B
C
B
B
D
B
YES
YES
YES
YES
YES
YES
YES
YES
NO
Not described
Corticosteroids:
Prednisolone• B YES
Antifungals:
Nystatin• 
Clotrimazole• 
Fluconazole• 
Ketoconazole• 
B
B
C
C
YES
YES
With caution
With caution
Sedatives:
Hypnotics, benzodiazepines• 
Barbiturates• 
Nitrous oxide• 
D
D
Not designated
NO, risk of craniofacial anomalies
NO, risk of craniofacial anomalies
Controversial
Table 1. Classification of the drugs most widely used in dental practice according to the fetal risk categories of the United States FDA.
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the permanent cessation of menstruation. As such, the 
term does not include interruptions in ovarian activity 
as a result of surgical interventions. Menopause usually 
occurs towards the fifth decade of life and has a series 
of physiological effects, with a reduction in estrogen 
output secondary to a loss of follicular function. It re-
presents a step within the slow and prolonged process of 
reproductive aging.
1) Oral alterations during menopause 
The alterations observed within the oral cavity are re-
lated to the hormone changes that take place in meno-
pausal women, though physiological aging of the oral 
tissues also plays a role. The most common oral mani-
festations during menopause are detailed below.
Periodontitis
In women, increased bone resorption due to endocrine 
causes appears to be the main pathogenic mechanism 
underlying accelerated bone loss in postmenopause (23-
27). However, no direct relationship has been observed 
between the two phenomena (24). The effects of 17-
beta-estradiol deficit in menopause have been related to 
the inflammatory reabsorption of alveolar bone, though 
this association remains unclear – particularly because 
of a lack of longitudinal studies designed to evaluate the 
clinical signs of gingival inflammation and the progres-
sion of periodontitis (24). Another marker linked to bone 
turnover in periodontal disease is osteocalcin. Bullon et 
al. (23), in a study of 39 postmenopausal women, found 
low serum osteocalcin levels to be significantly correla-
ted to a greater reduction in pocket depth and attachment 
loss after periodontal treatment. 
Maxillary osteonecrosis
Osteonecrosis of the jaws is observed in patients treated 
with bisphosphonates (BPs). These drugs are endoge-
nous pyrophosphate analogs that are able to affix to bone 
and inhibit osteoclast function, thereby lowering bone 
turnover and reducing active remodeling in those areas 
characterized by excessive bone reabsorption (28,29). 
The BPs can be administered via the intravenous route 
(for the prevention of bone metastases in cancer patients, 
in malignant hypercalcemia, and in multiple myeloma 
patients) or via the oral route (for the prevention and 
treatment of osteoporosis, and in some bone disorders 
such as Paget’s disease). Some examples of BPs mar-
keted in Spain are alendronate (Fosamax®, Fosavance®, 
Adrovance®, Alendrocare®, Bifoal®), risedronate (Acto-
nel®, Acrel®), etidronate (Difosfen®, Osteum®), clodro-
nate (Bonefos®), tiludronate (Skelid®) and ibandronate 
(Bonviva®).
Maxillary osteonecrosis produced by oral BP therapy is 
less frequent than that caused by systemic BPs, with an 
incidence of 1/10,000-1/100,000 in patients treated with 
oral BPs and 1-3% in patients treated with intravenous 
BPs (30). Although the risk of developing maxillary os-
teonecrosis in patients treated for osteoporosis is very 
low, a series of factors have been associated with an in-
creased risk of maxillary osteonecrosis (Table 3). The 
risk predicting capacity of each of these factors has not 
been established but is extremely low in absolute terms 
(31). Among patients treated with BPs at the doses used 
for osteoporosis, the risk of developing maxillary osteo-
necrosis is greater in those with past antecedents of maxi-
llary osteonecrosis, those receiving immune suppressive 
therapy, and those subjected to prolonged treatment 
CATEGORY A CATEGORY A/B CATEGORY B CATEGORY B*
NONSTEROIDAL 
ANTIINFLAMMATORY 
DRUGS
Paracetamol
Diclofenac
Ibuprofen
Naproxen
Ketoprofen
Rofecoxib
Acetylsalicylic 
acid
ANTIBIOTICS
Cephalosporins
Erythromycin
Amoxicillin
Azithromycin
Amoxicillin-clavu-
lanate
Tetracyclines
Streptomycin
Metronidazole
ANTIFUNGALS Fluconazole Ketoconazole
ANTIVIRAL AGENTS Aciclovir
ANTISEPTICS Chlorhexidine
SEDATIVES-HYPNO-
TICS DiazepamMidazolam Hydroxyzine
Table 2. Drug classification according to compatibility with lactation. A: compatible; B: use with caution; B*: insufficient data on excretion; 
C: totally contraindicated.
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with BPs. The following criteria must be met in order 
to establish a diagnosis of maxillary osteonecrosis (32): 
current or past treatment with BPs; the presence of one 
or more ulcerated lesions on the alveolar mucosa, with 
the exposure of maxillary or mandibular bone (there also 
may be cases without bone exposure, or with pain or 
fistulas, that should be studied more in detail); exposed 
bone of necrotic appearance; spontaneous presentation 
of the lesions or, more frequently, manifestation after 
dental-alveolar surgery (particularly extractions); and 
the absence of healing for a period of at least 6 weeks.
Clinically, maxillary osteonecrosis is usually charac-
terized by progressive and sustained pain requiring 
important analgesic doses (though the patient may be 
asymptomatic in the early stages), suppuration through 
gingival fistulas and the exposure of necrotic maxillary 
or mandibular bone (more frequent in the molar zone of 
the mandible) through the mucosa. In menopausal wo-
men with osteoporosis there have also been reports of 
oral mucosal ulcerations secondary to inadequate alen-
dronate administration (28).
In relation to the management of maxillary osteonecro-
sis, Bagán et al. (33) in 2009 proposed a modification 
of the staging classification used up to that time. Table 
4 shows the different clinical stages and the associated 
treatment options.
Burning mouth syndrome
Burning mouth syndrome (BMS), also known as glos-
sodynia or stomatodynia, mainly affects women in the 
fourth or fifth decade of life. The disorder shows a clear 
female predominance (7/1 over males)(34). BMS is des-
cribed as a burning sensation affecting different areas 
of the oral cavity (tongue, palate, lips, areas of dentu-
re support). It is often bilateral, and is characterized by 
Chemotherapy Cancer Immunotherapy Corticosteroids
Female sex: estrogens Old age Neurological damage Variations in atmospheric pressure
Osteoporosis Osteoarthritis Hypersensitivity reac-tions Hemodialysis
Blood dyscrasias Vascular diseases Coagulation alterations Systemic lupus erythe-matosus
Alcohol abuse Smoking Hypothyroidism Storage diseases
Arterial hypertension Malnutrition Infections Diabetes mellitus
Chronic inactivity Hyperlipidemia and adipose embolia
Drepanocytosis (sickle 
cell disease) Gaucher’s disease
Human immunodeficien-
cy virus infection
Dental risk factors: periapical disease, periodontal disease, dental abscesses, 
surgery affecting bone, trauma caused by poorly fitting dentures, traumatizing 
exostosis
Table 3. Possible risk factors for the development of maxillary osteonecrosis (17).
CLINICAL 
STAGE MANIFESTATIONS TREATMENT
STAGE 1
Bone exposure with necrotic bone or a small ulcera-
tion of the oral mucosa without exposure of necrotic 
bone. Both asymptomatic.
Daily 0.12% chlorhexidine rinse 
and follow-up.
STAGE 2A
Bone exposure with necrotic bone or a small oral fis-
tula without exposure of necrotic bone but exhibiting 
symptoms.
Controlled with antibiotics and antiseptics, and the le-
sions do not worsen.
Daily 0.12% chlorhexidine rinse, 
antibiotics, analgesics and follow-
up.
STAGE 2B
Bone exposure with necrotic bone or a small oral fis-
tula without exposure of necrotic bone but exhibiting 
symptoms.
Not controlled with drug treatment, the lesions wor-
sen, and pain is difficult to control.
Daily 0.12% chlorhexidine rinse, 
antibiotics, analgesics and sur-
gery, with elimination of the ne-
crotic bone.
STAGE 3 Mandibular fracture, extraoral fistula, osteolysis ex-tending to inferior margin.
Daily 0.12% chlorhexidine rinse, 
antibiotics, analgesics and wide 
surgery with bone resection.
Table 4. Proposed new classification of maxillary osteonecrosis due to bisphosphonates and its treatment.
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the absence of pathological findings. The accompanying 
symptoms may include dry mouth sensation or altera-
tions in taste sensation (34-37). The underlying causes 
remain unclear. It has been suggested that female sex 
hormones and neuropathic factors may be implicated, 
possibly through small-fiber sensory neuropathy of the 
mucosa oral (34). Normal clinical tests and explorations 
distinguish primary BMS from secondary stomatody-
nia. Treatment consists of low-dose topical (without 
swallowing) or systemic clonazepam. The association of 
this drug to tricyclic antidepressants has afforded varia-
ble results. 
Xerostomia
Xerostomia is another frequent manifestation in postme-
nopausal women. The patients typically report a decrea-
se in salivary flow, though in only one-third of all cases 
is hyposialia actually present (24). In a case-control stu-
dy of 46 postmenopausal women (38 with dry mouth 
sensation and 38 without xerostomia) published by 
Agha-Hosseini (24), a negative correlation was found 
between the severity of dry mouth sensation and the sali-
vary concentration of 17-beta-estradiol. In these patients 
abundant water intake is to be recommended, together 
with sugar-free sweets or chewing gum to increase sa-
livation. In some cases sialogogues such as pilocarpine, 
bromhexine or bethanechol may be indicated.
Other disorders
Oral lichen planus, benign mucosal pemphigoid and 
Sjögren’s syndrome are all disorders that have been re-
ported with increased frequency in menopausal women.
2) Dental management during menopause
A full clinical history should be compiled in all postme-
nopausal women, together with a thorough evaluation 
of the mucosal membranes, the periodontal and dental 
conditions, and salivary flow (quantity and quality). The 
pertinent complementary tests (X-rays, periodontal pro-
bing, sialometry) are also indicated. It is very important 
to maintain low levels of dental plaque by introducing 
adequate oral hygiene (use of interproximal brushes, 
dental floss, brushing frequency and technique), toge-
ther with the use of chemotherapeutic agents such as 
chlorhexidine. This substance reduces the accumula-
tion of dental plaque, improves periodontal disease and 
prevents caries (elimination of much of the presence of 
Streptococcus mutans), particularly root caries, which 
are more frequent in elderly individuals (23,29). The use 
of toothpastes, varnishes or gels containing fluor is also 
advised for the prevention of dental caries.
Dental management of patients receiving treatment with 
oral bisphosphonates
The oral management of these patients requires no special 
protocols. Conservative dental treatment can be provided 
at any time without having to suppress bisphosphonate 
therapy. In this context, tartrectomy, fillings, endodontic 
procedures, reconstructions and bridges can be indicated 
without having to adopt any specific preventive measu-
res. Regarding orthodontic treatment, the reduction or 
abolition of osteoclast function may seriously compro-
mise the results obtained. While such treatment can be 
considered, the patient informed consent document must 
explain that treatment failure is possible. In addition, 
such procedures should aim to minimize the number 
of extractions, dental movement and pressure upon the 
tissues during treatment and retention (38). In reference 
Fig. 2. Algorithm for dental management in patients treated with oral bisphosphonates
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to surgery involving underlying bone (scaling and pla-
ning, periodontal surgery, implants and extractions), the 
following groups are established according to the risk 
of maxillary osteonecrosis in each patient (time elapsed 
from the start of treatment with BPs and concomitant 
administration of immune suppressors - corticosteroids, 
azathioprine, cyclophosphamide, etc.)(Figure 2):
Group 1: Patients receiving oral BPs for at least • 
three years without immune suppressors. Any type 
of treatment can be provided, without the need for 
specific preventive measures. It is advisable to inform 
the patient about the existence of maxillary osteone-
crosis and its association to BPs and dental treatment, 
with signing of the corresponding informed consent 
document. In addition, periodic follow-up visits are 
required. 
Group 2: Patients receiving oral BPs for at least three • 
years and who are also using immune suppressors, or 
patients receiving oral BPs for more than years. The 
prescribing physician should be consulted in order to 
evaluate the possibility of suspending bisphosphona-
te therapy at least three months before oral surgery, 
except if the patient fracture risk is high (age > 70 
years, presence of previous fracture, densitometry 
with a T-score < -2.0) – in which case BP therapy 
should not be suspended. In the case of suspension, 
bisphosphonate treatment should be reintroduced as 
soon as healing is complete (2-3 months after).
Some authors have recommended the evaluation of 
serum CTX (collagen breakdown product released du-
ring bone remodeling and turnover), since bisphospho-
nate therapy reduces these levels; in this sense, CTX 
determination may be a reliable risk marker, though a 
number of studies have found no statistically signifi-
cant relationship between serum CTX and the number 
of areas of exposed necrotic bone or the magnitude of 
maxillary osteonecrosis (30).
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